Efficacy of pregabalin on the chemotherapy-induced neurotoxicity in patients with lung cancer
Not Applicable
- Conditions
- lung cancer
- Registration Number
- JPRN-UMIN000005829
- Lead Sponsor
- Juntendo University School of Medicine, Pulmonary Critical Care Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with renal dysfunction,Ccr<or =30ml/min 2.The patients taking the following drugs recommended by IASP Antidepressant/SSRI/SNRI/Antiepileptic agent/Opioid 3.Patients having the intracranial lesion with clinical symptoms 4.Patients with neuropathic pain by direct invasion of a tumor 5.Patient having the peripheral neuropathy caused by the etiology other than chemotherapy,VAS prior to the start of chemotherapy>or=30mm 6.Patients with past history of hypersensitivity to any of the ingredients in pregabalin 7.Patients with impaired consciousness 8.Patients with cardiac dysfunction 9.Other patients considered to be ineligible by the investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in VAS scale in neurotoxicity including pain and paresthesia before and 14 days after pregabalin administration.
- Secondary Outcome Measures
Name Time Method